ANGO
AngioDynamics, Inc.13.48
+0.14+1.05%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Key Stats
Market Cap
555.37MP/E (TTM)
-Basic EPS (TTM)
-0.78Dividend Yield
0%Recent Filings
8-K
CEO retirement deal signed
AngioDynamics locked in CEO James Clemmer's retirement via a February 3, 2026 agreement, keeping him in the role until a successor arrives or November 30, 2026. The board approved retention bonuses for execs: 150% of base salary for key leaders like CFO Trowbridge, 50% for others, payable after six months post-new CEO or June 1, 2027. Leadership stays steady. Transition risks successor hunt.
8-K
FY26 guidance reaffirmed
AngioDynamics' CEO presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026, affirming FY2026 guidance of $312-314M Med Tech net sales, up 14-16%, with adjusted EBITDA of $8-10M and positive free cash flow. Med Device stays flat at 0-1% growth, backed by a debt-free balance sheet with $41.6M cash. Strong pipeline targets $10.9B TAM by FY31.
8-K
Q2 sales beat, Med Tech soars
AngioDynamics posted Q2 FY2026 pro forma net sales of $79.4M, up 8.8% YoY, with Med Tech surging 13.0% to $35.7M on Auryon and NanoKnife strength, while gross margin hit 56.4%. Adjusted EBITDA doubled to $5.9M; raised FY2026 sales guidance to $312-314M. CEO Jim Clemmer to retire in FY2027. Med Tech powers profits.
10-Q
Q2 FY2026 results
AngioDynamics posted Q2 FY2026 revenue of $79.4M, up 9.0% y/y from $72.8M, with gross margin expanding to 56.4% from 54.8% on stronger Med Tech (13% growth to $35.7M) and Med Device (6% to $43.8M). Operating loss narrowed to $6.1M from $11.1M y/y, while net loss improved to $6.4M ($0.15/share) versus $10.7M ($0.26/share), reconciled to 41.5M diluted shares; YTD patterns align. Cash fell to $41.6M after $11.3M operating outflow, offset by $25M revolver availability (none drawn). Plant closure costs dropped yet persist. Revenue beats prior year. Litigation shadows port sales.
8-K
Shareholders approve directors, auditors
AngioDynamics shareholders at the November 10, 2025 annual meeting elected James C. Clemmer and Michael E. Tarnoff as Class I directors until 2028, with strong support of 29.6M and 29.2M votes for, respectively, versus minor withheld. They ratified Deloitte & Touche as auditors for fiscal 2026 (35.7M for) and approved executive comp on advisory basis (28.4M for). Governance stays steady.
IPO
Employees
Sector
Industry
AORT
Artivion, Inc.
45.91+0.54
ARAY
Accuray Incorporated
1.02-0.03
ATRC
AtriCure, Inc.
41.08+0.04
BDX
Becton, Dickinson and Company
196.39-3.70
HAE
Haemonetics Corporation
81.11+0.71
LMAT
LeMaitre Vascular, Inc.
83.41+0.64
MBOT
Microbot Medical Inc.
2.22+0.01
MMSI
Merit Medical Systems, Inc.
86.85+0.44
PEN
Penumbra, Inc.
308.10-1.05
SRDX
Surmodics, Inc.
42.98+0.00